Simpson K L, Spencer C M
Adis International Limited, Mairangi Bay, Auckland, New Zealand.
Drugs. 1999 May;57(5):759-65; discussion 766-7. doi: 10.2165/00003495-199957050-00013.
Insulin aspart is a recombinant analogue of human insulin. Following subcutaneous insulin injection (0.15 to 0.2 U/kg), significantly higher serum insulin concentrations are achieved in a shorter time with insulin aspart than with human insulin. The subsequent decline in serum insulin concentrations is also more rapid with insulin aspart. In healthy individuals undergoing euglycaemic glucose clamp testing, glucose infusion rates were higher and reached maximum concentrations significantly earlier after insulin aspart than after human insulin. Interindividual variability in pharmacodynamic and pharmacokinetic parameters with insulin aspart was generally less than that with human insulin, whereas the intraindividual variability in these parameters was similar after each insulin. In patients with type 1 diabetes postprandial glucose excursions were less pronounced with insulin aspart than human insulin. Daytime glucose control was better and minimum glucose levels during the night were not as low with insulin aspart as with human insulin. In diabetic patients treated with insulin aspart there was generally a lower frequency of hypoglycaemic events than in patients treated with human insulin.
门冬胰岛素是一种重组人胰岛素类似物。皮下注射胰岛素（0.15至0.2 U/kg）后，与重组人胰岛素相比，门冬胰岛素能在更短时间内使血清胰岛素浓度显著升高。随后门冬胰岛素导致的血清胰岛素浓度下降也更快。在进行正常血糖葡萄糖钳夹试验的健康个体中，与重组人胰岛素相比，门冬胰岛素注射后葡萄糖输注速率更高且达到最大浓度的时间显著更早。门冬胰岛素的药效学和药代动力学参数的个体间变异性通常小于重组人胰岛素，而每种胰岛素给药后这些参数的个体内变异性相似。在1型糖尿病患者中，与重组人胰岛素相比，门冬胰岛素引起的餐后血糖波动较小。门冬胰岛素的日间血糖控制更好，夜间最低血糖水平不像重组人胰岛素那样低。与使用重组人胰岛素治疗的患者相比，使用门冬胰岛素治疗的糖尿病患者低血糖事件的发生率通常更低。
